Is monthly retreatment with intravitreal bevacizumab (Avastin&reg;) necessary in neovascular age-related macular degeneration?

QR Code

Is monthly retreatment with intravitreal bevacizumab (Avastin&reg;) necessary in neovascular age-related macular degeneration?

Nicola G Ghazi, Tyler Q Kirk, Robert M Knape, James S Tiedeman, Brian P ConwayDepartment of Ophthalmology, University of Virginia Health System, Charlottesville, VA, USAPurpose: To report our short-term experience with bevacizumab in neovascular age-related macular degeneration (AMD) and recommend a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nicola G Ghazi, Tyler Q Kirk, Robert M Knape, et al
Format:	article
Language:	EN
Published:	Dove Medical Press 2010
Subjects:	Ophthalmology RE1-994
Online Access:	https://doaj.org/article/8fcfeaad584e4ce9ab50cf2d60b2a22e
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The effect of intravitreal bevacizumab (Avastin&reg;) on ocular pulse amplitude in neovascular age-related macular degeneration
by: Ehud Rechtman, et al.
Published: (2011)

Bevacizumab (Avastin&reg;) for the management of anterior chamber neovascularization and neovascular glaucoma
by: Dimitrios Brouzas, et al.
Published: (2009)

Pharmacokinetics of intravitreal bevacizumab (Avastin&reg;) in rabbits
by: Sinapis C, et al.
Published: (2011)

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
by: Juan Carlos Mesa Guti&eacute;rrez, et al.
Published: (2008)

Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin&reg;) for AMD followed by controlateral sympathetic ophthalmia
by: Dimitrios Brouzas, et al.
Published: (2009)

Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
by: Mamdouh M Kabeel, et al.
Published: (2008)

Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration
by: P William Conrad, et al.
Published: (2008)

Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization
by: Ioannis D Ladas, et al.
Published: (2008)

VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF BRANCH RETINAL VEIN OCCLUSION
by: Saquib Naeem, et al.
Published: (2019)

Use of nepafenac (Nevanac&reg;) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections
by: Eric Chen, et al.
Published: (2010)

Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab
by: Allegrini D, et al.
Published: (2021)

Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab
by: Palejwala NV, et al.
Published: (2014)

Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
by: Thapa R, et al.
Published: (2012)

Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results
by: Demir M, et al.
Published: (2011)

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
by: Jia-Kang Wang, et al.
Published: (2018)

Intravitreal ranibizumab for symptomatic drusenoid pigment epithelial detachment without choroidal neovascularization in age-related macular degeneration
by: Roberto Gallego-Pinazo, et al.
Published: (2011)

Histology of neovascular myopic macular degeneration
by: Shefali B. Jonas, et al.
Published: (2021)

Choroidal osteoma with choroidal neovascular membrane: Successful treatment with intravitreal bevacizumab
by: Neeraj Pandey, et al.
Published: (2010)

Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma
by: Marey HM, et al.
Published: (2011)

Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration
by: Elfandi S, et al.
Published: (2021)

Lucentis&reg; using Visudyne&reg; study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
by: Eric Chen, et al.
Published: (2010)

Timing of neovascular regression in eyes with high-risk proliferative diabetic retinopathy without macular edema treated initially with intravitreous bevacizumab
by: Shakarchi FI, et al.
Published: (2018)

Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization
by: Mansour AM, et al.
Published: (2012)

Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
by: Canut MI, et al.
Published: (2011)

Posterior capsule opacification and neovascularization treated with intravitreal bevacizumab and Nd:YAG capsulotomy
by: Grimelda Yuriana S&aacute;nchez-Castro, et al.
Published: (2008)

Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choroidal osteoma
by: Kubota-Taniai M, et al.
Published: (2011)

Intravitreal bevacizumab injection and carotid artery stent replacement for neovascular glaucoma in internal carotid artery occlusion
by: Aya Kodama, et al.
Published: (2010)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
by: Dimitrios A Karagiannis, et al.
Published: (2009)

Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.
by: Wei Wang, et al.
Published: (2014)

Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
by: Jeon S, et al.
Published: (2014)

Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion
by: Ito Y, et al.
Published: (2015)

Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
by: Hahn P
Published: (2014)

Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration
by: Pukhraj Rishi, et al.
Published: (2011)

Revisiting the Utility of Dilated Fundus Exams in Patients with Neovascular Age-Related Macular Degeneration Receiving Regular Intravitreal Injections
by: Antaki F, et al.
Published: (2021)

Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration
by: Luis Arias, et al.
Published: (2010)

Baseline central macular thickness predicts the need for retreatment with intravitreal triamcinolone plus laser photocoagulation for diabetic macular edema
by: O&#39;Day R, et al.
Published: (2013)

Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
by: Hidetaka Matsumoto, et al.
Published: (2021)

Radiation therapy for neovascular age-related macular degeneration
by: Robert Petrarca, et al.
Published: (2011)

Hemiretinal vein occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab
by: Yalamanchi S, et al.
Published: (2011)

Proteins from Avastin® (bevacizumab) show tyrosine nitrations for which the consequences are completely unclear.
by: Jia Wan, et al.
Published: (2012)